In hi-myc prostate tumors aged to 2 months, Mertk KO mice have increased dead cells, suggesting that Mertk KO tumors have decreased prostate cancer efferocytosis in vivo (Fig. 4G). This evidence concerns the gene MERTK and prostate cancer.